| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| PMA | index of prevalence and severity of gingivitis, where P = papillary gingiva, M = marginal gingiva, a... |
|---|---|
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
| EF | ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e... |
| PF | pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid... |
| CAP | camptodactyly-arthropathy-pericarditis [syndrome]; Canada Assistance Plan; capsule; captopril; catab... |
| AVR | Aortic Valve Replacement |
|---|---|
| CRRT | Continuous Renal Replacement Therapy |
| CRRTs | Continuous renal replacement therapies |
| DVR | Double Valve Replacement |
| ERT | Enzyme replacement therapy |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| acetate replacement factor | <biochemistry> 1,2 dithiolane 3 valeric acid. Regarded as a coenzyme in the oxoglutarate dehydrogenase complex of the citric acid cycle. Involved generally in oxidative decarboxylations of _ keto acids. A growth factor for some organisms. (18 Nov 1997) |
|---|
| arthroplasty, replacement | Partial or total replacement of a joint. (12 Dec 1998) |
|---|---|
| arthroplasty, replacement, hip | Replacement of the hip joint. (12 Dec 1998) |
| arthroplasty, replacement, knee | Replacement of the knee joint. (12 Dec 1998) |
| renal replacement therapy | Procedures which temporarily or permanently remedy insufficient cleansing of body fluids by the kidneys. (12 Dec 1998) |
| replacement | 1. The act of replacing. 2. <chemistry> The removal of an edge or an angle by one or more planes. Source: Websters Dictionary (01 Mar 1998) |
| replacement bone | A bone that develops in a cartilage environment after the latter is partially or entirely destroyed by calcification and subsequent resorption. Synonym: cartilage bone, replacement bone. (05 Mar 2000) |
| replacement fibrosis | The formation of fibrous tissue that occupies sites where various other cells and tissues have become atrophied, or degenerated and necrotic. (05 Mar 2000) |
| replacement therapy | Therapy designed to compensate for a lack or deficiency arising from inadequate nutrition, from certain dysfunctions (e.g., glandular hyposecretion), or from losses (e.g., haemorrhage); replacement may be physiological or may entail administration of a substitute (e.g., a synthetic oestrogen in place of estradiol). (05 Mar 2000) |
| replacement vector | A cloning vector, such as a bacteriophage, in which some of the DNA of the vector can be replaced with foreign DNA. (09 Oct 1997) |
| hip replacement | Surgery to replace all or part of the hip joint with an artificial device that re-establishes normal hip joint motion. Indicated in cases of severe intractable degenerative arthritis (DJD). (27 Sep 1997) |
| hormone replacement therapy | In females, treatment with sex hormones for a number for reasons, including menopause, partial or full hysterectomy, or amenorrhoea.In women, treatment with sex hormones is indicated for a number of reasons, including menopause, partial or full hysterectomy, or amenorrhoea. After menopause, conjugated oestrogens, estradiol, or estrone sulfate are given to reduce pain during intercourse, limit blood vessel effects, and prevent loss of bone mass. After radical hysterectomy, conjugated oestrogens are given for similar reasons. After menopause or partial hysterectomy, progestin is administered at the same time to offset an increased risk of endometrial cancer. In some amenorrhoeas, oestrogen is given to restore menses; if the therapy is unsuccessful, this may indicate the presence of pathology, for instance, pituitary tumour. Benefits for postmenopausal women include a lowered risk of heart attack (oestrogen lowers LDL and raises HDL levels), and prevention of osteoporosis, since the rate of bone loss is directly linked to a drop in oestrogen levels (see perimenopause). Medical opinion about the hazard posed by such therapy remains divided. Some studies have indicated increased incidence of breast cancer; however, a comprehensive 1992 review of the literature contradicted this finding. (05 Mar 2000) |
| oestrogen replacement therapy | <endocrinology, gynaecology> The use of oestrogenic substances in postmenopausal or other oestrogen-deficient women to alleviate effects of hormone deficiency, such as vasomotor symptoms, dyspareunia, and progressive development of osteoporosis. (12 Dec 1998) |
| ossicular replacement | Surgical insertion of an implant to replace one or more of the ear ossicles. (12 Dec 1998) |
| total knee joint replacement | Surgery involving the replacement of the knee joint with artificial components which reestablishes normal joint function. Indicated in cases of severe knee fracture or degenerative arthritis (DJD) unresponsive to medical therapy. (27 Sep 1997) |
| energy replacement time | <radiobiology> Time required for a plasma to lose (via radiation or other loss mechanisms) an amount of energy equal to its average kinetic energy. (09 Oct 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|